Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.

Authors: Ugel, S  Scarselli, E  Iezzi, M  Mennuni, C  Pannellini, T  Calvaruso, F  Cipriani, B  De Palma, R  Ricci-Vitiani, L  Peranzoni, E  Musiani, P  Zanovello, P  Bronte, V 
Citation: Ugel S, etal., Blood. 2010 Feb 18;115(7):1374-84. doi: 10.1182/blood-2009-07-233270. Epub 2009 Nov 10.
Pubmed: (View Article at PubMed) PMID:19903903
DOI: Full-text: DOI:10.1182/blood-2009-07-233270

Telomerase reverse transcriptase (TERT) is a good candidate for cancer immunotherapy because it is overexpressed in 85% of all human tumors and implicated in maintenance of the transformed phenotype. TERT-based cancer vaccines have been shown to be safe, not inducing any immune-related pathology, but their impact on tumor progression is modest. Here we show that adoptive cell therapy with the use of high-avidity T lymphocytes reactive against telomerase can control the growth of different established tumors. Moreover, in transgenic adenocarcinoma mouse prostate mice, which develop prostate cancer, TERT-based adoptive cell therapy halted the progression to more aggressive and poorly differentiated tumors, significantly prolonging mouse survival. We also demonstrated that human tumors, including Burkitt lymphoma, and human cancer stem cells, are targeted in vivo by TERT-specific cytotoxic T lymphocytes. Effective therapy with T cells against telomerase, different from active vaccination, however, led to autoimmunity marked by a consistent, although transient, B-cell depletion in primary and secondary lymphoid organs, associated with alteration of the spleen cytoarchitecture. These results indicate B cells as an in vivo target of TERT-specific cytotoxic T lymphocytes during successful immunotherapy.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11038656
Created: 2016-02-18
Species: All species
Last Modified: 2016-02-18
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.